15-16th November 2017

Berlin, Germany

Speakers from 2016

Expand/Collapse

Garlich Von Essen
Secretary General
European Seed Association

Garlich is German and studied Agriculture and Economics at the University of Göttingen. He started his professional career in the European Commission’s DG Agriculture before graduating in Administrative and Political Sciences from the College of Europe. Before joining the seed industry in 1999, he worked in the European Parliament in agricultural and structural policy, specifically on the EU’s R&D policy and funding instruments. Joining ESA as Director Public Affairs, he became Secretary General in 2004. In ESA, Garlich takes responsibility for the overall management of the association and its staff, the development of strategic policy campaigns on ESA’s priority issues and the positioning of Europe’s seed industry vis-à-vis EU and international bodies and decision makers.

Day Two

Wednesday 26th October, 2016

09.10 | Panel Discussion: Navigating the Regulatory Environment for CRISPR as Novel Breeding Technique

Tristan Félix
Research Assistant
Institut Imagine

Day One

Tuesday 25th October, 2016

11.40 | Digital Droplet PCR: A Tool to Quantify CRISPR/Cas9 Mediated Genomic Deletions

Dirk Daelemans
Associate Professor
Rega Institute, KU Leuven

Day One

Tuesday 25th October, 2016

15.10 | Identifying & Validating the Cellular Target of Bioactive Molecules by CRISPR/Cas Genome Editing

Daniel Anderson
Sam Goldblith Associate Professor
MIT

Day Two

Wednesday 26th October, 2016

09.55 | Keynote Session: Nucleic Acid Delivery Systems for RNA Therapy and Gene Editing

Donald Apanovitch
Director, Functional Genomics & Biolomics
Pfizer

Workshop A

Monday 24th October, 2016

09.00 | Enhancing CRISPR Technology for Target Identification and Developing Genome-Wide CRISPR Libraries within Oncology

Day Two

Wednesday 26th October, 2016

14.25 | Keynote Session: Strategies & Applications Using CRISPR and RNAi Technologies for Identification of Novel Oncology Druggable Targets

Bill Lundberg
Chief Scientific Officer
CRISPR Therapeutics

Day Two

Wednesday 26th October, 2016

12.25 | Bringing CRISPR Therapeutics into the Clinic

Ross Kettleborough
European Field Applications Specialist
Twist Bioscience

Day One

Tuesday 25th October, 2016

09.10 | A CRISPR Screen Identifies Genetic Vulnerabilities in Acute Myeloid Leukaemia

Danilo Maddalo
Lab Head, Oncology Pharmacology
Novartis Institutes for BioMedical Research

Workshop B

Monday 24th October, 2016

13.00 | Developing More Physiologically-Relevant Disease Models With CRISPR for Improved Preclinical Predictability

Day One

Tuesday 25th October, 2016

14.10 | Genome Editing Meets Mouse Modelling for Better Preclinical Tools

Lennart Randau
Research Group Leader, Terrestrial Microbiology
Max-Planck-Institute

Day One

Tuesday 25th October, 2016

10.10 | Modulating the Architecture of Minimal Type I CRISPR-Cas Interference Complexes

John Feder
Associate Director, Genome Biology
Bristol-Myers Squibb

Day One

Tuesday 25th October, 2016

17.25 | Close of Day 1

09.00 | Chairman’s Opening Remarks

Day Two

Wednesday 26th October, 2016

17.10 | Chair’s Closing Remarks

10.55 | Development and Optimisation of CRISPR Gene Editing for Drug Discovery Applications

09.10 | Panel Discussion: Navigating the Regulatory Environment for CRISPR as Novel Breeding Technique

09.00 | Chairman’s Opening Remarks

John van der Oost
Professor, WU Agrotechnology & Food Sciences
Wageningen UR

Day One

Tuesday 25th October, 2016

09.40 | Understanding the Mechanistic Actions of Cpf1 to Optimise Efficiency of CRISPR Precision Genome Editing

Beat Späth
Director Agricultural Biotechnology
EuropaBio

Day Two

Wednesday 26th October, 2016

09.10 | Panel Discussion: Navigating the Regulatory Environment for CRISPR as Novel Breeding Technique

Jonathan Chesnut
Senior Director, Synthetic Biology R&D
Thermo Fisher Scientific

Day One

Tuesday 25th October, 2016

12.40 | CRISPR-Based Genome Editing Tools: New Applications & Improved Workflows

Evren Alici
Assistant Professor & Research Group Leader
Karolinska Institutet

Day Two

Wednesday 26th October, 2016

15.10 | Harnessing CRISPR Genome Editing for the Development of Cancer Immunotherapies

Roderick Beijersbergen
Group Leader, Division of Molecular Carcinogenesis & NKI Robotics
The Netherlands Cancer Institute

Day One

Tuesday 25th October, 2016

14.40 | The Possibilities, Challenges & Success of CRISPR-Based Screening for Target Identification

Laurent Poirot
Head of Early Discovery
Cellectis

Day Two

Wednesday 26th October, 2016

11.25 | TALEN-Based Genome Editing for Adoptive T-Cell Therapies

Emma Shanks
Head of Screening
The Beatson Institute

Day One

Tuesday 25th October, 2016

12.10 | Transitioning From siRNA Screens to CRISPR Screens: Experiences From The Beatson Institute

Leigh Brody
Director Genomic Services
Desktop Genetics

Leigh is the Director of Genomic Services at Desktop Genetics, and is responsible for delivering CRISPR genome editing projects and services to the company’s customers around the world. Dr Brody is also responsible for facilitating collaborations with industry and academia for experimental CRISPR genome-editing research projects. She holds a PhD from Imperial College London from the Metabolic and Molecular Imaging Group and a BSc from Simmons College. She also worked at the Broad Institute establishing the R&D platform for the RNAi Consortium, working on TRC1, TRC2 and the Achilles Project. She previously was at Index Ventures working on early-stage investment strategies for life science companies. Prior to this, Dr Brody headed preclinical development at start-up biotechnology company Global Acorn, which was formed as a result of her graduate work to develop a patented cancer-targeting nanoparticle.

Day Two

Wednesday 26th October, 2016

16.10 | Interactive Workshop Hosted by Twist Bioscience

Daniela Hüber
Gene Modulation Specialist, Dharmacon
GE Healthcare

Day Two

Wednesday 26th October, 2016

13.55 | CRISPR-Cas9 Screening with Arrayed Synthetic crRNA Libraries

Niels Geijsen
Founder & Scientific Advisor
NTrans

Prof. dr. Niels Geijsen is leading the research team that has developed iTOP. His lab focuses on understanding genetic neuromuscular disorders, including Muscular Dystrophies like Duchenne Muscular Dystrophy and FSHD. His work was published in high ranking journals, including Nature, Cell and Science. He did his post-doctoral training at The Whitehead Institute and subsequently obtained a tenure- track faculty position at the Harvard Stem Cell Institute, where he developed novel methods for the genetic manipulation of human stem cells. In 2010 he became Professor of Regenerative Medicine at Utrecht University and relocated his research lab to the Hubrecht Institute where he and his team developed the iTOP technology.

Day Two

Wednesday 26th October, 2016

11.55 | iTOP: A Novel Non-Viral Delivery System for Gene-Editing Based Therapeutics

Charles Joseph
Product Manager
Twist Bioscience

Charles is a Product Manager with over five years’ life science marketing experience. Before joining Twist, he was a product manager for Kapa Biosystems and Agilent Technologies. He received his B.S. in Bioengineering: Biotechnology from the University of California, San Diego and Masters of Biotechnology from San Jose State University.

Day Two

Wednesday 26th October, 2016

16.10 | Interactive Workshop Hosted by Twist Bioscience

Kosuke Yusa
Group Leader
Wellcome Trust Sanger Institute

Day One

Tuesday 25th October, 2016

09.10 | A CRISPR Screen Identifies Genetic Vulnerabilities in Acute Myeloid Leukaemia